SCHEMBL14545927

SCHEMBL14545927

Cn1cnc2cc(CNc3cc(N[C@H]4CCCC[C@H]4I)nc4c(Br)cnn34)ccc21

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 11/20 0.43
▸ CDK2 P24941 5/20 0.41
▸ CDK7 P50613 2/20 0.40
▸ POLB P06746 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ CCNH P51946 1/20 0.38
▸ MNAT1 P51948 1/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11930874 0.90 GSK3B (0.42) GSK3BCDK2CDK7POLBGAA
SCHEMBL14516595 0.86 GSK3B (0.39) GSK3BCDK2CDK7POLBGAA
SCHEMBL11930883 0.79 CDK2 (0.43) GSK3BCDK2CDK7POLBGAA
SCHEMBL11930865 0.79 GSK3B (0.65) GSK3BCDK2
SCHEMBL11930866 0.78 GSK3B (0.63) GSK3BCDK2CDK7CCNE1CCNH
SCHEMBL12953004 0.78 CDK2 (0.39) GSK3BCDK2CDK7POLBGAA
SCHEMBL11930875 0.77 CDK2 (0.64) GSK3BCDK2CCNE1
SCHEMBL14043226 0.77 CDK2 (0.54) GSK3BCDK2CDK7CCNE1CCNH
SCHEMBL12954030 0.77 CDK2 (0.54) GSK3BCDK2CDK7CCNE1CCNH
SCHEMBL14043244 0.75 CDK2 (0.40) GSK3BCDK2CDK7POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007044449-A2 NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2007-04-19 — — WO disclosed
Send feedback